← Leaderboards
Mitchell Geffner
University Of California Los Angeles
$2,313,044
Attributed
$2,313,044
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $74.2K · FY2005–09$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$2,313,044 · 11
By mechanism
M01$2,313,044 · 11
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- William M Pardridge$11,519,163
- Michael David Collins$2,143,595
- Susanne B Nicholas$2,245,233
- Robert B Ettenger$858,654
- Gail A Greendale$20,206,655
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchChild (0-11)Drug Screening /EvaluationHuman SubjectHuman Therapy EvaluationHormone TherapySomatotropinPediatric PharmacologyPituitary DwarfismEndocrine Disorder ChemotherapyPostnatal Growth DisorderLongitudinal Human StudyBody CompositionClinical Trial Phase IFundingSourceResourcesUnited States National Institutes Of HealthPeptide Hormone MetabolismInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseGrantResearch PersonnelBase
Grant awards (19)
CLINICAL TRIAL: STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D$52,177
M01 · FY2009 · RR · contact PI
EVAL OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND ADRENOMEDULLARY FUNCTION$22,029
M01 · FY2009 · RR · contact PI
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): TREATMENT$69,700
M01 · FY2008 · RR · contact PI
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): TREATMENT$56,208
M01 · FY2007 · RR · contact PI
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): TREATMENT$29,395
M01 · FY2006 · RR · contact PI
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): TREATMENT$5,166
M01 · FY2005 · RR
PROLEASE ADMINISTERED IN GROWTH HORMONE DEFICIENT CHILDREN$207,266
M01 · FY2001 · RR
SAFETY AND EFFICACY OF GROWTH HORMONE FROM ADOLESCENCE TO ADULTHOOD$207,266
M01 · FY2001 · RR
PHASE I/II MULTICENTER, OPEN LABEL STUDY OF THE EFFICACY OF PROLEASE HGH$207,266
M01 · FY2001 · RR
DOSE RANGING STUDY OF MK-0677 IN GROWTH HORMONE DEFICIENT CHILDREN$207,266
M01 · FY2001 · RR
SAFETY AND EFFICACY OF GROWTH HORMONE FROM ADOLESCENCE TO ADULTHOOD$207,266
M01 · FY2001 · RR
OPEN-LABEL, LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF PROLEASE HGH$207,266
M01 · FY2001 · RR
OPEN-LABEL, LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF PROLEASE HGH$207,266
M01 · FY2001 · RR
PROLEASE ADMINISTERED IN GROWTH HORMONE DEFICIENT CHILDREN$207,266
M01 · FY2000 · RR
DOSE RANGING STUDY OF MK-0677 IN GROWTH HORMONE DEFICIENT CHILDREN$207,266
M01 · FY2000 · RR
PHASE I/II MULTICENTER, OPEN LABEL STUDY OF THE EFFICACY OF PROLEASE HGH$207,266
M01 · FY2000 · RR
PHASE I/II MULTICENTER, OPEN LABEL STUDY OF THE EFFICACY OF PROLEASE HGH$1,903
M01 · FY2000 · RR
PROLEASE ADMINISTERED IN GROWTH HORMONE DEFICIENT CHILDREN$1,903
M01 · FY2000 · RR
DOSE RANGING STUDY OF MK-0677 IN GROWTH HORMONE DEFICIENT CHILDREN$1,903
M01 · FY2000 · RR